Research map: Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer

Back to the article

Papers in this map

  1. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial · Massimo Cristofanilli · 2016 · 1868 citations · Cited by this paper
  2. Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance · 2025 · Related
  3. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications · Nida Iqbal · 2014 · 1414 citations · Cited by this paper
  4. Microbiome-driven PKs: redefining drug metabolism beyond host enzymes · 2026 · Related
  5. Targeting the PI3K pathway in cancer: are we making headway? · Filip Jankú · 2018 · 1059 citations · Cited by this paper
  6. Combined oral contraceptives and pharmacokinetic drug interactions: impact on efficacy and safety · 2026 · Related
  7. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer · Todd W. Miller · 2010 · 557 citations · Cited by this paper
  8. Predicting the potential for organic cation transporter 1-mediated drug–drug interactions with fenoterol by amitriptyline, fluoxetine, selegiline, metformin, and verapamil · 2026 · Related
  9. Breast Cancer: Current Molecular Therapeutic Targets and New Players · Siddavaram Nagini · 2017 · 531 citations · Cited by this paper
  10. Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial · 2025 · Related
  11. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer · Ana Bosch · 2015 · 445 citations · Cited by this paper
  12. Evaluation of the drug-drug interaction between low-dose methotrexate and short-term use of non-steroidal anti-inflammatory drugs · 2025 · Related
  13. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study · Matthew J. Ellis · 2015 · 241 citations · Cited by this paper
  14. GLP-1RA PHARMACOKINETICS AND CLINICAL EFFECTS: FOCUS ON CARDIAC, VASCULAR, AND GLOMERULAR STRUCTURES · 2026 · Related
  15. The present and future of PI3K inhibitors for cancer therapy · Pau Castel · 2021 · 233 citations · Cited by this paper
  16. Modifying Hy’s Law and eDISH for the modern idiosyncratic DILI era · 2025 · Related
  17. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing · Hua Yu · 2023 · 207 citations · Cited by this paper
  18. Exploring the influence of sex on idiosyncratic DILI: impact on risk assessment · 2026 · Related
  19. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma · Zheling Chen · 2017 · 174 citations · Cited by this paper
  20. Complex in vitro model developers’ perspective on advanced hepatic in vitro culture methods for predictive drug safety · 2026 · Related
  21. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα · Emily J. Hanan · 2022 · 155 citations · Cited by this paper
  22. An emerging generation of endocrine therapies in breast cancer: a clinical perspective · Rima D Patel · 2023 · 148 citations · Cited by this paper
  23. RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy · Kyung W. Song · 2021 · 124 citations · Cited by this paper
  24. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials · Mirko K. Fillbrunn · 2022 · 74 citations · Cited by this paper
  25. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials · Rola El Sayed · 2019 · 72 citations · Cited by this paper
  26. The PIK3CA Gene as a Mutated Target for Cancer Therapy · John P. Gustin · 2008 · 59 citations · Cited by this paper
  27. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review · DRAGICA PAVLOVIC · 2023 · 45 citations · Cited by this paper
  28. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer · Komal L. Jhaveri · 2024 · 38 citations · Cited by this paper
  29. Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer · Antonella Ferro · 2024 · 29 citations · Cited by this paper
  30. Endocrine therapies for breast and prostate cancers · Geneviève Chaput · 2022 · 27 citations · Cited by this paper
  31. Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC). · Philippe Lucien Bedard · 2022 · 15 citations · Cited by this paper
  32. Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer · Joyce A O'Shaughnessy · 2025 · 13 citations · Cited by this paper
  33. INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA -mutated (mut) locally advanced or metastatic breast cancer (LA/mBC). · Dejan Juric · 2024 · 9 citations · Cited by this paper
  34. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer · Albert Grinshpun · 2024 · 8 citations · Cited by this paper
  35. Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER + HER2 − Breast Cancer · Liqin Ping · 2025 · 6 citations · Cited by this paper
  36. Abstract PO2-19-09: INAVO122: a Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients with PIK3CA-mutated, HER2-positive advanced breast cancer · Sandra M. Swain · 2024 · 2 citations · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)